AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.5300
-0.1000 (-3.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 2.6300
Open 2.6300
Bid 0.0000 x 1800
Ask 0.0000 x 800
Day's Range 2.4600 - 2.6369
52 Week Range 1.5600 - 9.2000
Volume 164,322
Avg. Volume 2,501,796
Market Cap 40.118M
Beta (3Y Monthly) 1.17
PE Ratio (TTM) N/A
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE 23 days ago

    FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet

    - Biotech and healthcare stocks are loved by traders for their big price moves, which can happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks into the headlines. Recent examples include Mustang Bio (MBIO) and Akari Therapeutics (AKTX) with their respective human study results.

  • GlobeNewswire 26 days ago

    Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases

    In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants.

  • GlobeNewswire 29 days ago

    Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

    Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease.

  • ACCESSWIRE 29 days ago

    Positive News in The Biotech, Social Media, Financial & Cannabis Sectors Help the Market Towards New Highs

    CORAL GABLES, FL / ACCESSWIRE / April 23, 2019 / The stock market is on the verge of setting new record highs today April 23, 2019. Today we are highlighting: Akari Therapeutics, Plc (AKTX), Twitter Inc. (TWTR), Bank of America Corporation (BAC), Leafbuyer Technologies, Inc. (LBUY). Akari Therapeutics, Plc (AKTX) (Market Cap: $65.409M) traded higher on Tuesday 4/23/2019 after making a big announcement.

  • GlobeNewswire 29 days ago

    Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces positive initial Phase II clinical data from the first three of bullous pemphigoid (BP) patients in an ongoing clinical trial.

  • GlobeNewswire 2 months ago

    Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will provide an update on its eye diseases program during the 2019 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) being held April 28-May 2, 2019 in Vancouver, B.C. A poster will be presented at ARVO showing Coversin’s effect in a preclinical model of autoimmune uveitis, a back of the eye orphan disease with significant unmet need.

  • ACCESSWIRE 2 months ago

    These Tech Stocks Could Test March Highs

    CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The tech stock market is truly miraculous, mainly because the tech industry never ceases to amaze consumers as companies consistently demonstrate their ability to innovate towards the future. Over the course of the last few months, we've seen tech companies design and invent in the areas of data analytics, artificial intelligence, augmented reality, and a plethora of others. ParcelPal Technology Inc (PTNYF) (PKG), Conformis Inc (CFMS), Digital Turbine Inc (APPS), and Akari Therapeutics Plc (AKTX) represent 4 tech stocks on the rise on Monday.

  • ACCESSWIRE 2 months ago

    These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19)

    CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The future of the tech stock market directly related to the ability of companies in the tech industry to combat the growing obstacles facing humanity. In ...

  • GlobeNewswire 2 months ago

    Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that it had a successful Type B, pre-IND meeting with the Food and Drug Administration (FDA) regarding Akari’s proposed pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

  • GlobeNewswire 3 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • GlobeNewswire 6 months ago

    Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced recent developments and supporting data which underscore the differentiation of Coversin. “We are encouraged by new data that demonstrates the potential for improved patient comfort and ease of use. Alongside this focus on patient convenience we continue to develop Coversin as a differentiated treatment by means of its combined complement C5 and LTB4 inhibitory activity with early data readouts of our bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) trials expected in first quarter 2019,” said Clive Richardson, Interim Chief Executive Officer of Akari Therapeutics.

  • GlobeNewswire 6 months ago

    Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announced that PASylated Coversin data will be presented at the 2nd Annual 2018 Complement-Based Drug Development Summit in Boston, Mass. during an oral presentation by Andrew Luster, M.D., Ph.D., Chief, Division of Rheumatology, Allergy and Immunology & Director, Center for Immunology and Inflammatory Diseases Massachusetts General Hospital. Akari currently has two clinical programs open in bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) where both C5 and LTB4 are believed to be implicated.

  • GlobeNewswire 6 months ago

    Akari Announces Third Quarter 2018 Financial Results and Business Highlights

    Four ongoing clinical trial programsTwo clinical programs expected to report initial data in first quarter 2019Long-term clinical study continues to yield encouraging safety.